This is a preview of subscription content, log in via an institution to check access.
Notes
International Society for Pharmacoeconomics and Outcomes Research
References
Sullivan W, et al. The Cost Effectiveness of Idelalisib in Chronic Lymphocytic Leukaemia in England and Wales. 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN141, 7 Nov 2015. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=43431
Gouveia M, et al. Cost-Effectiveness of Idelalisib in Combination with Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (Cll) in Portugal. 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN180, 7 Nov 2015. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=42075
Leleu H, et al. Cost-Effectiveness of Idelalisib plus Rituximab in Chronic Lymphocytic Leukaemia. 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN173, 7 Nov 2015. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=43230
Kumar G, et al. A Scotland Based Cost-Effectiveness Analysis of Idelalisib (Zydelig(R)) in Combination with Rituximab for the Treatment of Adults with Chronic Lymphocytic Leukaemia Cll). 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN143, 7 Nov 2015. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=43471
Rights and permissions
About this article
Cite this article
Idelalisib plus rituximab cost effective for CLL in Europe. PharmacoEcon Outcomes News 742, 22 (2015). https://doi.org/10.1007/s40274-015-2650-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2650-4